What's in A.O. Ospedale Papa Giovanni XXIII's pipeline?

A.O. Ospedale Papa Giovanni XXIII has 4 drugs in our index: 2 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 1 in Phase 1.

Which companies overlap with A.O. Ospedale Papa Giovanni XXIII's portfolio?

Top competitors by shared drug class: National Institute of Allergy and Infectious Diseases (NIAID), Pfizer, University of Guadalajara, ViiV Healthcare.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/a-o-ospedale-papa-giovanni-xxiii.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-18 · How we verify

A.O. Ospedale Papa Giovanni XXIII — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A.O. Ospedale Papa Giovanni XXIII pipeline: 2 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 1 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
fludarabine, cyclophosphamide, doxorubicin, rituximab	fludarabine, cyclophosphamide, doxorubicin, rituximab	marketed
Rilpivirine + darunavir/cobicistat	Rilpivirine + darunavir/cobicistat	marketed	Antiretroviral combination (NNRTI + protease inhibitor + pharmacokinetic booster)	HIV reverse transcriptase, HIV protease	Infectious Disease (HIV/AIDS)
stable HAART	stable HAART	phase 3	Antiretroviral		Infectious Diseases

Therapeutic area mix

Infectious Disease (HIV/AIDS) · 1
Infectious Diseases · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

National Institute of Allergy and Infectious Diseases (NIAID) · 1 shared drug class
Pfizer · 1 shared drug class
University of Guadalajara · 1 shared drug class
ViiV Healthcare · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for A.O. Ospedale Papa Giovanni XXIII:

Cite this brief

Drug Landscape (2026). A.O. Ospedale Papa Giovanni XXIII — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/a-o-ospedale-papa-giovanni-xxiii. Accessed 2026-05-18.